RxDoctor Payments Data

Leopoldo Velasco

Psychiatric/Mental Health · Bell Gardens, CANPI 1326112194

Payments from drug & device makers

$4,656in general payments, 2019–2025

Across 147 payments — averaging $31.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Alkermes, Inc.$1K
  • E.r. Squibb & Sons, L.L.C.$620
  • Otsuka America Pharmaceutical, Inc.$601
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$522
  • Teva Pharmaceuticals USA, Inc.$270
  • plus $282 from 3 others

What the payments were for

  • Food & beverage$4,62999%
  • Education$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,656 in reported general payments places this provider in the 90th percentile of 2,433 psychiatric/mental health providers in California.

See all psychiatric/mental health providers in California

Medicare billing

Part B allowed, 2024
$24,382
Medicare patients
49
Services billed
208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole49$75,869
Invega SustennaPaliperidone Palmitate27$64,399
AristadaAripiprazole Lauroxil12$20,932
Lurasidone Hcl18$15,645
Aripiprazole166$6,142
Prazosin Hcl57$1,418
Quetiapine Fumarate90$1,387
Venlafaxine Hcl ErVenlafaxine Hcl22$1,203
Buspirone Hcl162$1,050
Trazodone Hcl137$995
Olanzapine52$947
Benztropine Mesylate94$658
Duloxetine Hcl60$635
Mirtazapine106$628
Hydroxyzine Pamoate44$453

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$601$75,86949 claims
Johnson & JohnsonInvega Sustenna$1,249$64,39927 claims
Alkermes, Inc.Aristada$1,112$20,93212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,433 psychiatric/mental health providers in California.

Other psychiatric/mental health in Bell Gardens

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →